Table 3.

Univariate analysis for overall survival at 18 months.

	n	Hazard Ratio	95% confidence interval	P-value
First line steroids to Pentostatin, days
<=10 days	20	Reference
>10 days	40	1.1	0.6-2.0	0.8
Pentostatin used as
second line therapy	22	Reference
third line therapy	38	0.9	0.5-1.7	0.8
Age at Pentostatin
<=60 years	46	Reference
>60 years	14	1.9	1.01-3.7	0.045
Female-to-male gender Mismatch
No	35	Reference
Yes	25	0.7	0.2-1.9	0.4
Donor type
HLA-matched related	19	0.7	0.2-2.2	0.5
HLA-matched unrelated	35
Haploidentical	3
Cord blood	3
Graft source
Bone marrow	10	Reference
Peripheral blood	46	1.3	0.6-2.9	0.5
Cord blood	4	Excluded
Conditioning
Myeloablative	38	Reference
Non-myeloablative	22	1.4	0.8-2.6	0.2
Overall grade (at diagnosis)
Grade 2	11	Reference
Grade 3-4	49	1.9	0.9-4.3	0.1
GVHD organs
Skin (Reference no skin)	12	2	1.02-4.1	0.04
UGI (Reference no UGI)	27	0.95	0.5-1.7	0.9
LGI (Reference no LGI)	47	0.4	0.2-0.8	0.01
Liver (Reference no liver)	26	1.9	1.05-3.3	0.03
GVHD organ combination
LGI only	28	Reference
Liver only	10	3.3	1.4-7.3	0.004
LGI + Liver	10	1.4	0.6-3.3	0.4
LGI + Liver + Skin	6	3.1	1.02-9.6	0.05
Skin + LGI	4	2.5	0.96-6.3	0.06
Skin only	1	Excluded
Skin + Liver	1	Excluded